Baidu
map

肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CSMO 2014 ：NK/T细胞淋巴瘤诊治新进展

2014-07-09 中山大学肿瘤防治中心 黄慧强 白冰 医学论坛网

NK淋巴瘤细胞
关注

在7月4日的第八届中国肿瘤内科大会会上，中山大学肿瘤防治中心的黄慧强教授作了“NK/T细胞淋巴瘤诊治新进展---中国医生的贡献”的主题报告。   结外NK/T细胞淋巴瘤(extranodal natural/killer T-cell lymphoma, ENKTL)属于结外非霍奇金淋巴瘤 (NHL)的一种少见特殊类型,ENKTL亚洲多

在7月4日的第八届中国肿瘤内科大会会上，中山大学肿瘤防治中心的黄慧强教授作了“NK/T细胞淋巴瘤诊治新进展---中国医生的贡献”的主题报告。  

结外NK/T细胞淋巴瘤(extranodal natural/killer T-cell lymphoma, ENKTL)属于结外非霍奇金淋巴瘤 (NHL)的一种少见特殊类型,ENKTL亚洲多见,尤以中国，在所有淋巴瘤亚型中，比例可达6%,，而在欧美国家少见，其好发于中年男性,中位年龄45岁。ENKTL预后不佳，经典的国际预后指数 (International Prognostic Index，IPI)可用于ENKTL的预后评估。新的预后指标(Korean Prognostic Index，KPI) 基于临床分期、区域淋巴结受累、LDH和B症状而设计。与IPI相比，KPI能够更好的区分不同危险度的患者，并具有更合理、均匀的患者分布。

ENKTL恶性度高，对常规化疗敏感度相对较低，预后不佳。早期疾病以放射治疗为主，部分患者可以达到长期无病生存，中晚期疾病及复发难治性疾病采用以化疗为主的综合治疗，预后较差。而我国学者在ENKTL的综合治疗上做出了大量的努力，也获得了一定的成就，部分成就也得到了国际同仁的认可。

尽管ENKTL侵袭性强，预后不佳。迄今仍未有标准的治疗方法，但近年我国学者做出了大量的贡献，NK/T淋巴瘤的治疗效果有了比较明显的提高。对于早期局部的ENKTL，采用局部放疗为主联合诱导化疗效果较好，晚期患者以全身化疗为主，含L-ASP的化疗方案越来越受到重视，笔者认为像PEG-ASP（培门冬酶）联合Gemox这样简单有效的方案，很值得推广。自体造血干细胞移植巩固治疗有助改善高危的初治患者及对化疗敏感的复发患者远期生存，而靶向治疗和其他治疗值得我们共同努力，进一步探索。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2024710, encodeId=cfa22024e10a1, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Sun May 03 06:10:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702369, encodeId=5b431e0236968, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Fri Mar 13 20:10:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057510, encodeId=43df205e5109b, content=<a href='/topic/show?id=8ae712834d8' target=_blank style='color:#2F92EE;'>#NK/T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12834, encryptionId=8ae712834d8, topicName=NK/T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Sat Mar 28 05:10:00 CST 2015, time=2015-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372607, encodeId=7f7a13e260787, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18028, encryptionId=7d2d1802820, topicName=T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Fri Jul 11 00:10:00 CST 2014, time=2014-07-11, status=1, ipAttribution=)]
    2015-05-03 liuhuangbo

    #SMO#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2024710, encodeId=cfa22024e10a1, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Sun May 03 06:10:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702369, encodeId=5b431e0236968, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Fri Mar 13 20:10:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057510, encodeId=43df205e5109b, content=<a href='/topic/show?id=8ae712834d8' target=_blank style='color:#2F92EE;'>#NK/T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12834, encryptionId=8ae712834d8, topicName=NK/T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Sat Mar 28 05:10:00 CST 2015, time=2015-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372607, encodeId=7f7a13e260787, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18028, encryptionId=7d2d1802820, topicName=T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Fri Jul 11 00:10:00 CST 2014, time=2014-07-11, status=1, ipAttribution=)]
    2015-03-13 marlenexl

    #细胞淋巴瘤#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2024710, encodeId=cfa22024e10a1, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Sun May 03 06:10:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702369, encodeId=5b431e0236968, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Fri Mar 13 20:10:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057510, encodeId=43df205e5109b, content=<a href='/topic/show?id=8ae712834d8' target=_blank style='color:#2F92EE;'>#NK/T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12834, encryptionId=8ae712834d8, topicName=NK/T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Sat Mar 28 05:10:00 CST 2015, time=2015-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372607, encodeId=7f7a13e260787, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18028, encryptionId=7d2d1802820, topicName=T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Fri Jul 11 00:10:00 CST 2014, time=2014-07-11, status=1, ipAttribution=)]
    2015-03-28 gongliu

    #NK/T细胞淋巴瘤#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2024710, encodeId=cfa22024e10a1, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Sun May 03 06:10:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702369, encodeId=5b431e0236968, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Fri Mar 13 20:10:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057510, encodeId=43df205e5109b, content=<a href='/topic/show?id=8ae712834d8' target=_blank style='color:#2F92EE;'>#NK/T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12834, encryptionId=8ae712834d8, topicName=NK/T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Sat Mar 28 05:10:00 CST 2015, time=2015-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372607, encodeId=7f7a13e260787, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18028, encryptionId=7d2d1802820, topicName=T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Fri Jul 11 00:10:00 CST 2014, time=2014-07-11, status=1, ipAttribution=)]
    2014-07-11 aliceclz

    #T细胞淋巴瘤#

    0

相关资讯

ASCO 2014：循环EBV-DNA水平可动态预测ENKL的治疗效果

摘要号：8562 第一作者：梁超勇，中山大学附属肿瘤医院 标题：早期的阴性循环EB病毒DNA可作为鼻型结外NK/T细胞淋巴瘤（ENKL）的生存预测。 背景：对于具有高侵袭性和不良预后的鼻型结外NK/ T细胞淋巴瘤（ENKL），预测肿瘤标志物是十分必要的。本次的前瞻性研究旨在通过循环EB病毒DNA浓度的动态监测值的评估对ENKL进行预测。 方法：从200

Baidu
map
Baidu
map
Baidu
map